Short pages

Jump to navigation Jump to search

Showing below up to 50 results in range #21,651 to #21,700.

View ( | ) (20 | 50 | 100 | 250 | 500)

  1. (hist) Anidulafungin warnings and precautions [438 bytes]
  2. (hist) Mafenide microbiology [438 bytes]
  3. (hist) Amitriptyline hydrochloride dosage forms and strengths [438 bytes]
  4. (hist) Amitriptyline hydrochloride nonclinical toxicology [438 bytes]
  5. (hist) Amitriptyline hydrochloride clinical studies [438 bytes]
  6. (hist) Air embolism classification [438 bytes]
  7. (hist) Chronic diarrhea CT [438 bytes]
  8. (hist) Mastoiditis Screening [438 bytes]
  9. (hist) Diphyllobothriasis other imaging findings [438 bytes]
  10. (hist) Membrane bound o-acyltransferase domain containing 2 [438 bytes]
  11. (hist) TMIGD1 [438 bytes]
  12. (hist) Neurexophilin and pc-esterase domain family member 2 [438 bytes]
  13. (hist) POEMS syndrome screening [438 bytes]
  14. (hist) COVID-19 approach to patients with elevated biomarkers [438 bytes]
  15. (hist) Analgesic nephropathy screening [438 bytes]
  16. (hist) Aminoquinolines [439 bytes]
  17. (hist) 2nd Skin [439 bytes]
  18. (hist) Micturition syncope [439 bytes]
  19. (hist) Alphos [439 bytes]
  20. (hist) Test-retest [439 bytes]
  21. (hist) Fibrin sealant [439 bytes]
  22. (hist) IRB [439 bytes]
  23. (hist) Research council for complementary medicine [439 bytes]
  24. (hist) Rush-Copley Medical Center [439 bytes]
  25. (hist) Hydrocollator [439 bytes]
  26. (hist) Alexander's law [439 bytes]
  27. (hist) Aortic valve disease [439 bytes]
  28. (hist) Stomach cancer future or investigational therapies [439 bytes]
  29. (hist) Stomach cancer cost-effectiveness of therapy [439 bytes]
  30. (hist) Pelvic inflammatory disease cost-effectiveness of therapy [439 bytes]
  31. (hist) Pelvic inflammatory disease future or investigational therapies [439 bytes]
  32. (hist) Myxoma medical therapy [439 bytes]
  33. (hist) Blue rubber bleb nevus syndrome primary prevention [439 bytes]
  34. (hist) Stomach cancer case study one [439 bytes]
  35. (hist) Congenital adrenal hyperplasia due to 21-hydroxylase deficiency cost-effectiveness of therapy [439 bytes]
  36. (hist) Congenital adrenal hyperplasia due to 21-hydroxylase deficiency future or investigational therapies [439 bytes]
  37. (hist) Congenital adrenal hyperplasia due to 21-hydroxylase deficiency case study one [439 bytes]
  38. (hist) Polycythemia screening [439 bytes]
  39. (hist) Membranoproliferative glomerulonephritis surgery [439 bytes]
  40. (hist) Varicocele physical examination [439 bytes]
  41. (hist) Kyasanur forest disease primary prevention [439 bytes]
  42. (hist) Pelvic inflammatory disease case study one [439 bytes]
  43. (hist) Perforated eardrum surgery [439 bytes]
  44. (hist) Adefovir labels and packages [439 bytes]
  45. (hist) Fidaxomicinindications and usage [439 bytes]
  46. (hist) Methysergide dosage forms and strengths [439 bytes]
  47. (hist) Methysergide clinical studies [439 bytes]
  48. (hist) Methysergide labels and packages [439 bytes]
  49. (hist) Drug (patient information) [439 bytes]
  50. (hist) Diffuse large B cell lymphoma secondary prevention [439 bytes]

View ( | ) (20 | 50 | 100 | 250 | 500)